ChengDa Pharmaceuticals Co. Ltd. (301201) — Net Asset Quality Index
ChengDa Pharmaceuticals Co. Ltd. (301201) has a Net Asset Quality Index of 90.2% as of March 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥2.33 Billion minus total liabilities of CN¥228.13 Million yields net assets of CN¥2.10 Billion. A higher index indicates a stronger, lower-leverage balance sheet. Read debt load of ChengDa Pharmaceuticals Co. Ltd. for a breakdown of total debt and financial obligations.
Quality Index
Net Assets
Total Assets
Total Liabilities
ChengDa Pharmaceuticals Co. Ltd. Net Asset Quality Index Over Time (2019–2025)
This chart shows how ChengDa Pharmaceuticals Co. Ltd.'s Net Asset Quality Index has evolved across 7 annual periods from 2019 to 2025. As of March 2026, the index stands at 90.2%, representing net assets of CN¥2.10 Billion against total assets of CN¥2.33 Billion CNY. For live market cap and overall valuation, see ChengDa Pharmaceuticals Co. Ltd. (301201) total market value.
Annual Net Asset Quality Index for ChengDa Pharmaceuticals Co. Ltd. (2019–2025)
The table below presents the year-by-year Net Asset Quality Index for ChengDa Pharmaceuticals Co. Ltd. from 2019 to 2025, covering 7 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. See shareholders equity of ChengDa Pharmaceuticals Co. Ltd. for net asset value and shareholders' equity analysis.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 89.2% | CN¥2.10 Billion | CN¥2.35 Billion | CN¥252.83 Million | ▲ +1.2 pp |
| 2024 | 88.1% | CN¥2.15 Billion | CN¥2.44 Billion | CN¥290.77 Million | ▼ -4.7 pp |
| 2023 | 92.8% | CN¥2.28 Billion | CN¥2.46 Billion | CN¥176.40 Million | ▼ -2.6 pp |
| 2022 | 95.4% | CN¥2.22 Billion | CN¥2.32 Billion | CN¥105.81 Million | ▲ +17.9 pp |
| 2021 | 77.6% | CN¥529.93 Million | CN¥683.23 Million | CN¥153.30 Million | ▼ -8.3 pp |
| 2020 | 85.9% | CN¥458.91 Million | CN¥534.21 Million | CN¥75.30 Million | ▲ +20.5 pp |
| 2019 | 65.4% | CN¥357.35 Million | CN¥546.56 Million | CN¥189.21 Million | — |